Cargando…

Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature

Cabozantinib, a tyrosine kinase inhibitor, was approved by the US Food and Drug Administration in November 2012, for the treatment of metastatic medullary thyroid carcinoma. Although side effects typically include stomatitis, palmar-plantar erythrodysesthesia syndrome, hypertension and diarrhea, mos...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapur, Sakshi, Xiao, Han, Zakowski, Maureen F., Hameed, Meera R., Levin, Miles B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649879/
https://www.ncbi.nlm.nih.gov/pubmed/29147383
http://dx.doi.org/10.14740/wjon779w
_version_ 1783272624567091200
author Kapur, Sakshi
Xiao, Han
Zakowski, Maureen F.
Hameed, Meera R.
Levin, Miles B.
author_facet Kapur, Sakshi
Xiao, Han
Zakowski, Maureen F.
Hameed, Meera R.
Levin, Miles B.
author_sort Kapur, Sakshi
collection PubMed
description Cabozantinib, a tyrosine kinase inhibitor, was approved by the US Food and Drug Administration in November 2012, for the treatment of metastatic medullary thyroid carcinoma. Although side effects typically include stomatitis, palmar-plantar erythrodysesthesia syndrome, hypertension and diarrhea, most patients are able to tolerate the recommended dose of 140 mg daily. Surgical resection is the primary treatment for medullary thyroid carcinoma. Patients with metastatic disease, who are not candidates for surgery, are considered candidates for systemic therapy. However, systemic chemotherapy has a limited role in metastatic disease. Our paper highlights not only the malignant potential of a medullary thyroid carcinoma, but also the role of cabozantinib in patients with progressive metastatic disease. We report two cases of patients with progressive metastatic medullary thyroid carcinoma (involving lung, lymph nodes, liver, pancreas, brain and spine) who responded well to therapy with cabozantinib.
format Online
Article
Text
id pubmed-5649879
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-56498792017-11-16 Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature Kapur, Sakshi Xiao, Han Zakowski, Maureen F. Hameed, Meera R. Levin, Miles B. World J Oncol Case Report Cabozantinib, a tyrosine kinase inhibitor, was approved by the US Food and Drug Administration in November 2012, for the treatment of metastatic medullary thyroid carcinoma. Although side effects typically include stomatitis, palmar-plantar erythrodysesthesia syndrome, hypertension and diarrhea, most patients are able to tolerate the recommended dose of 140 mg daily. Surgical resection is the primary treatment for medullary thyroid carcinoma. Patients with metastatic disease, who are not candidates for surgery, are considered candidates for systemic therapy. However, systemic chemotherapy has a limited role in metastatic disease. Our paper highlights not only the malignant potential of a medullary thyroid carcinoma, but also the role of cabozantinib in patients with progressive metastatic disease. We report two cases of patients with progressive metastatic medullary thyroid carcinoma (involving lung, lymph nodes, liver, pancreas, brain and spine) who responded well to therapy with cabozantinib. Elmer Press 2014-04 2014-05-06 /pmc/articles/PMC5649879/ /pubmed/29147383 http://dx.doi.org/10.14740/wjon779w Text en Copyright 2014, Kapur et al. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Kapur, Sakshi
Xiao, Han
Zakowski, Maureen F.
Hameed, Meera R.
Levin, Miles B.
Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
title Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
title_full Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
title_fullStr Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
title_full_unstemmed Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
title_short Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
title_sort metastatic medullary thyroid carcinoma and cabozantinib: case series and review of literature
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649879/
https://www.ncbi.nlm.nih.gov/pubmed/29147383
http://dx.doi.org/10.14740/wjon779w
work_keys_str_mv AT kapursakshi metastaticmedullarythyroidcarcinomaandcabozantinibcaseseriesandreviewofliterature
AT xiaohan metastaticmedullarythyroidcarcinomaandcabozantinibcaseseriesandreviewofliterature
AT zakowskimaureenf metastaticmedullarythyroidcarcinomaandcabozantinibcaseseriesandreviewofliterature
AT hameedmeerar metastaticmedullarythyroidcarcinomaandcabozantinibcaseseriesandreviewofliterature
AT levinmilesb metastaticmedullarythyroidcarcinomaandcabozantinibcaseseriesandreviewofliterature